Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
25.01
+0.91 (+3.78%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor Inc
< Previous
1
2
3
Next >
Xencor Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
October 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Upcoming Change to Board of Directors
October 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 11, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
September 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2024 Financial Results
August 05, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
June 13, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2024 Financial Results
May 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
February 28, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
February 20, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Xencor, Inc.
Via
Business Wire
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
January 02, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
November 07, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
November 03, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
October 31, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
October 26, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Present Multiple Posters at the SITC Annual Meeting
September 27, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
September 19, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
July 27, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
May 30, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2023 Financial Results
May 08, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
May 01, 2023
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.